Adding the numbers, since they settle part of this. A quick sanity check on any figure quoted here: is it mean or median, is it intention-to-treat or completers, and what was the comparator. Three questions, and they resolve most disagreements in these threads.
One thing that is still open after hyun_seoul’s answer:
Why the interval is four weeks rather than two, and whether a slower ladder gets to the same place?
PharmacoVig_BOS said:A quick sanity check on any figure quoted here: is it mean or median, is it intention-to-treat or completers, and what was the comparator.
Adding the part of the answer the thread has not reached. The gap between trial results and real-world results is consistent and it is not fraud. Trial participants get titration by protocol, scheduled contact, free drug and dietetic support; removing that infrastructure costs a few percentage points every time it has been measured. When your own curve sits below the published mean, that is the likeliest explanation before anything about you or your material.
That is the short version; the long version is somebody else's post.
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsOP back with an update, since a thread like this is useless without one.
Closing this out: I held the step for six weeks rather than four and it settled without a dose change. The interval was the answer, not the dose.
MASHdoc_SA said:The gap between trial results and real-world results is consistent and it is not fraud.
That is right for the weekly injectables. For the daily agents the interval logic is different and the four-week convention does not transfer.
Worth separating that from the trial evidence, which this thread keeps folding into the same question. They behave differently and the advice does not transfer.